ERBA Diagnostics, Inc. announced that on November 22, 2016, Philippe Gadal, a member of the Board of Directors of the company, and the chairman of the Audit Committee of the Board, delivered notice to the company of his intention to resign from the Board effective as of December 31, 2016. Effective as of January 1, 2017, Hayden Jeffreys will become the Interim Chief Executive Officer of the company. Mr. Jeffreys has served as a director on the Board since May 31, 2016, and he plans to continue serving in that role too.

Mr. Jeffreys has twenty years of experience in the clinical diagnostics industry, with specialization in the molecular diagnostic and blood bank fields. Mr. Jeffreys currently serves as the Commercial Director for the Molecular Diagnostics Division and Vice President Business Development and Strategy for ERBA Diagnostics Mannheim GmbH, and he plans to continue serving in that role too. Prior to joining ERBA Mannheim, Mr. Jeffreys served in a variety of positions for companies involved in the diagnostics industry, including: Commercial Director for Lumora Ltd. from 2012 through 2015; Divisional Director Diagnostic Products for Lab21 Healthcare from 2008 through 2012; and, prior thereto, various positions at Invitron Ltd., Kronus Inc. and Gen-Probe UK Ltd.